5 курс / Психиатрия и наркология для детей и взрослых (доп.) / Клиническая_психофармакогенетика_Р_Ф_Насырова,_Н_Г
.pdfГлава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
8.1. Фармакогенетика вальпроевой кислоты |
Рис. 1.2. Алгоритм персонализированного назначения препаратов ВК (продолжение) [3].
273
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
Глава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
8.1. Фармакогенетика вальпроевой кислоты |
Рис. 1.4. Алгоритм персонализированного назначения препаратов ВК (окончание) [3].
275
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
Глава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
8.1. Фармакогенетика вальпроевой кислоты |
||
the rat// Prog Neuropsychopharmacol Biol Psychiatry. 1982; |
47.\ Tong V. Valproic acid II: effects on oxidative stress, |
||
6(3):223-33. PMID: 6815713. |
|
|
mitochondria membrane potential,and cytotoxicity in glu- |
32.\ Johannessen CU, Johannessen SI. Valproate: |
tathione-depleted rat hepatocytes //Toxicol. Sci. 2005; |
||
past, present, and future// CNS Drug Rev. 2003 Sum- |
86,436–443. doi:10.1093/toxsci/kfi185 |
||
mer;9(2):199-216. PMID: 12847559. |
|
48.\ Pourahmad J., Eskandari M. R., Kaghazi A., Shaki |
|
33.\ VanDongen A.M., VanErp M.G., Voskuyl R.A. |
F., Shahraki J. & Fard J. K. A new approach on valproic acid |
||
Valproate reduces excitability by blockage of |
sodium |
induced hepatotoxicity: involvement of lysosomal membrane |
|
and potassium conductance // Epilepsia. 1986 May- |
leakiness and cellular proteolysis// Toxicol. In Vitro. 2012; 26, |
||
Jun;27(3):177-182. PMID: 3084227 |
|
545–551 (2012). doi:10.1016/j.tiv.2012.01.020 |
|
34.\ Haerian B.S., Baum L., Kwan P., Tan H.J., Ray- |
49.\ Mitchell S., Ellingson C., Coyne T., Hall L., Neill M., |
||
mond A.A., Mohamed Z. SCN1A, SCN2A and SCN3A gene |
Christian N. et al. Genetic variation in the urea cycle: a mod- |
||
polymorphisms and responsiveness to antiepileptic drugs: |
el resource for investigating key candidate genes for com- |
||
a multicenter cohort study and meta-analysis // Phar- |
mon diseases// Hum. Mutat. 30, 57–60 (2009). doi:10.1002/ |
||
macogenomics. 2013 Jul;14(10):1153-1166. doi:10.2217/ |
humu.20813 |
||
pgs.13.104. |
|
|
50.\ Aires C.C., van Cruchten A., Ijlst L., de Almei- |
35.\ Haerian B.S., Baum L, Tan H.J., Kwan P., Ray- |
da I. T., Duran M., Wanders R. J. et al. New insights on the |
||
mond A.A., Saruwatari J., Nakagawa K., Mohamed Z. SC- |
mechanisms of valproate-induced hyperammonemia: in- |
||
N1A IVS5N+5 polymorphism and response to sodium val- |
hibition of hepatic N-acetylglutamate synthase activity by |
||
proate: a multicenter study// Pharmacogenomics. 2012 |
valproyl-CoA// J. Hepatol. 2011;55, 426–434. doi:10.1016/j. |
||
Oct;13(13):1477-1485. doi: 10.2217/pgs.12.127. |
|
jhep.2010.11.031 |
|
36.\ Li X., Zhang J., Wu X., Yan H., Zhang Y., He R.H., |
51.\ Janicki P. K., Bezinover D., Postula M., Thompson |
||
Tang Y.J. et al. Polymorphisms of ABAT, SCN2A and ALDH5A1 |
R. S., Acharya J., Acharya V. et al. Increased occurrence |
||
may affect valproic acid responses in the treatment of epi- |
of valproic acid-induced hyperammonemia in carriers of |
||
lepsy in Chinese // Pharmacogenomics.2016;17:2007–2014. |
T1405N polymorphism in carbamoyl phosphate synthetase |
||
37.\ Lv N., Qu J., Long H., Zhou L., Cao Y., Long L., Liu |
1 gene// ISRN Neurol 2013, 1–4 . doi:10.1155/2013/261497 |
||
Z. et al.. Association study between polymorphisms in the |
52.\ Stewart J. D., Horvath R., Baruffini E., Ferrero L., |
||
CACNA1A, CACNA1C, and CACNA1H genes and drug-resis- |
Bulst S., Watkins P. B. et al. Polymerase γ Gene POLG de- |
||
tant epilepsy in the Chinese Han population// Seizure. 2015 |
termines the risk of sodium valproate-induced liver toxicity. |
||
Aug;30:64-9. doi: 10.1016/j.seizure.2015.05.013. |
|
//Hepatology. 2010; 52, 1791–1796. doi:10.1002/hep.23891 |
|
38.\ Göttlicher M., Minucci S., Zhu P., Krämer O.H., |
53.\ Saneto R.P., Lee I.C., Koenig M.K., Bao X., Weng |
||
Schimpf A., Giavara S., Sleeman J.P. et al.Valproic acid de- |
S.W., Naviaux R.K. et al. POLG DNA testing as an emerging |
||
fines a novel class of HDAC inhibitors inducing differentiation |
standard of care before instituting valproic acid therapy for |
||
of transformed cells// EMBO J. 2001 Dec 17;20(24):6969- |
pediatric seizure disorders// Seizure. 2010; 19, 140–146. |
||
6978. PMID: 11742974. |
|
|
doi:10.1016/j.seizure.2010.01.002 |
39.\ Chavez-Blanco A., |
Perez-Plasencia |
C., Pe- |
54.\ Hsieh C.L., Chen K.C., Ding C.Y., Tsai W.J., Wu |
rez-Cardenas E., Carrasco-Legleu C., Rangel-Lopez E., |
J F. & Peng C.C. Valproic acid substantially downregulat- |
||
Segura-Pacheco B. et al. Antineoplastic effects of the DNA |
ed genes folr1, IGF2R, RGS2, COL6A3, EDNRB, KLF6, and |
||
methylation inhibitor hydralazine and the histone deacetyl- |
pax-3, N-acetylcysteine alleviated most of the induced gene |
||
ase inhibitor valproic acid in cancer cell lines // Cancer Cell. |
alterations in chickenembryo model// Rom. J. Morphol. Em- |
||
2006; Int. 6, 2.doi:10.1186/1475-2867-6-2. |
|
bryol.2013; 54, 993–1004. doi:10.1016/j.tox.2011.10.015. |
|
40.\ Liu H., Dong H., Robertson K., Liu C. DNA methyla- |
55.\ Ogusu N., Saruwatari J., Nakashima H. et al. Im- |
||
tion suppresses expression of the urea cycle enzyme carba- |
pact of the superoxide dismutase 2 Val16Ala polymorphism |
||
moyl phosphate synthetase 1 (CPS1) in human hepatocellu- |
on the relationship between valproic acid exposure and el- |
||
lar carcinoma //Am J Pathol. 2011 Feb;178(2):652-661. doi: |
evation of γ-glutamyltransferase in patients with epilepsy: |
||
10.1016/j.ajpath.2010.10.023. |
|
|
a population pharmacokinetic-pharmacodynamic analy- |
41.\ Yagi M., Nakamura T., Okizuka Y., Oyazato Y., Kawa- |
sis // PLoS One. 2014; 9(11):e111066. doi:10.1371/journal. |
||
saki Y., Tsuneishi S., et al. Effect of CPS1 4217C>a genotype |
pone.0111066. |
||
on valproic-acid-induced hyperammonemia// Pediatr Int. |
56.\ Yagi M., Nakamura T., Okizuka Y., Oyazato Y., Kawa- |
||
2010;52:744–748. doi:10.1111/j.1442-200x.2010.03157.x. |
saki Y. Tsuneishi S., Sakaeda T. et al. Effect of CPS14217C>A |
||
42.\ Hudson G. Mitochondria DNA polymerase-γ and |
genotype on valproic-acid-induced hyperammonemia // |
||
human disease // Hum. Mol. Genet.2006; 15,244–252. |
Pediatrics international : official journal of the Japan Pedi- |
||
doi:10.1093/hmg/ddl233 |
|
|
atric Society. 2010; 52 (5): 689-854. doi: 10.1111/j.1442- |
43.\ Sitarz K.S., Elliott |
H.R., Karaman B.S., Relton |
200X.2010.03157.x. |
|
C., Chinnery P.F. & Horvath, R. Valproic acid triggers in- |
57.\ Villegas-Martínez I., de-Miguel-Elízaga I., Carras- |
||
creased mitochondria biogenesis in POLG-deficient fibro- |
co-Torres R., Marras C., Canteras-Jordana M., Yedra-Guz- |
||
blasts //Mol. Genet. Metab.2014; 112, 57–63. doi:10.1016/j. |
mán M.J., Martínez-Villanueva M. et al. The COL1A1 SP1 |
||
ymgme.2014.03.006 |
|
|
polymorphism is associated with lower bone mineral den- |
44.\ Hynynen J., Komulainen T., Tukiainen E., Nordin A., |
sity in patients treated with valproic acid // Pharmacog- |
||
Arola J., Kalviainen R. et al. Acute liver failure after valproate |
enet Genomics. 2016 Mar; 26(3):126-132. doi: 10.1097/ |
||
exposure in patients with POLG1 mutations and theprogno- |
FPC.0000000000000199. |
||
sis after liver transplantation// Liver Transpl. 2014;20, 1402– |
58.\ Li H., Wang X., Zhou Y., Ni G., Su Q., Chen Z., Chen |
||
1412. doi:10.1002/lt.23965 |
|
|
Z. et al. Association of LEPR and ANKK1 Gene Polymor- |
45.\ Fukushima Y., Seo T., Hashimoto N., Higa Y., Ishitsu |
phisms with Weight Gain in Epilepsy Patients Receiving Val- |
||
T. & Nakagawa K. Glutathione-S-transferase (GST) M1 null |
proic Acid // Int JNeuropsychopharmacol. 2015 Mar 3; 18(7): |
||
genotype and combined GSTM1 and GSTT1 null genotypes |
pyv021. doi: 10.1093/ijnp/pyv021. |
||
are risk factors for increased serum γ-glutamyltransferase in |
59.\ Lee S.Y., Chen S.L., Wang T.Y., Chang Y.H., Chen |
||
valproic acid-treated patients// Clin. Chim. Acta. 2008;389, |
P.S, Huang S.Y., Tzeng N.S. et al. The COMT Val158Met |
||
98–102. doi:10.1016/j.cca.2007.11.035 |
|
Polymorphism Is Associated With Response to Add-on |
|
46.\ Nanau R. M. & Neuman M. G. Adverse drug reac- |
Dextromethorphan Treatment in Bipolar Disorder // J Clin |
||
tions induced by valproic acid// Clin. Biochem. 2013; 46, |
Psychopharmacol. 2017 Feb; 37(1):94-98. doi: 10.1097/ |
||
1323–1338. doi:10.1016/j.clinbiochem.2013.06.012 |
|
JCP.0000000000000633. |
|
|
|
|
277 |
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/